

# Feasibility trial: temporary reduction in the number of antiviral medicines people with both HIV and HBV infection need to take

<b>Submission date</b> 24/05/2022	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 08/08/2022	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 14/04/2025	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Most people with HIV take three antiviral drugs to control the virus. Increasingly, with modern antivirals, many people with HIV now only need to take two drugs. This can have benefits – for example, the commonly used drug tenofovir disoproxil fumarate (TDF) sometimes affects the kidneys or bones in the long term, so using a two drug combination without TDF might avoid these side effects. However, people who have both HIV and hepatitis B virus (HBV) together are usually recommended to take three drugs including tenofovir. This is because tenofovir is an effective treatment for both HIV and HBV. As part of an antiviral combination, tenofovir suppresses growth of both viruses, as shown by undetectable HIV and HBV viral loads in the blood. People who have dual infection with HIV and HBV and who don't take tenofovir are at risk of rising HBV viral loads causing liver inflammation (hepatitis). This can lead to tummy pain and vomiting and, if not treated, result in serious problems such as liver failure.

Recently, new HBV markers in blood, called pgRNA and HBcrAg, have been discovered. We can use these new markers to more accurately group people who have undetectable HBV viral loads on treatment into two groups: those with very low levels of HBV viral growth, where the pgRNA and HBcrAg are not detected, and those with low but ongoing levels of viral growth, where pgRNA or HBcrAg are detected. People with very low levels of viral growth can more likely stop tenofovir safely without the HBV viral load rising. In contrast, those with low levels of HBV viral growth should continue tenofovir. This has been shown in people with HBV who do not have HIV.

### Who can participate?

Patients who are HIV-1 antibody and HBsAg positive and receiving tenofovir or entecavir.

### What does the study involve?

We will recruit 12 people who have both HBV and HIV with undetectable viral loads of both viruses. In those with very low levels of HBV viral growth, as shown by the new HBV markers, we will stop tenofovir for 6 months and continue the other antiviral drugs. We will confirm whether

this treatment approach is safe by closely monitoring for any new medical problems and taking regular blood tests, including liver tests and HBV viral loads. After 6 months, tenofovir will be restarted.

What are the possible benefits and risks of participating?

Benefits:

There are unlikely to be direct benefits of stopping tenofovir for 6 months to people taking part in this study. However, if we find that temporarily stopping tenofovir is safe and acceptable, these results will help us set up a larger trial to provide more information as to whether this strategy of reducing treatment is effective. This in turn could improve the treatment options for people with HIV and HBV in future.

Risks:

1. The main risk relates to temporary discontinuation of the antiviral drug tenofovir leading to an increase in the level of HBV DNA and in turn elevated liver function tests and liver flare.

However this risk will be minimised through multiple steps:

(a) selection of participants with well compensated liver disease who have undetectable levels of HBV DNA, HBV pgRNA and HBcrAg, indicating a very high level of HBV control with minimal risk of ALT flare off tenofovir or entecavir

(b) continuation of lamivudine or emtricitabine, which provides some anti-HBV activity

(c) close monitoring after tenofovir/entecavir withdrawal through liver tests and HBV DNA levels to pick up any liver flare early and reintroduce tenofovir/entecavir rapidly if needed to prevent any significant harm

(d) reintroduction of tenofovir/entecavir after 24 weeks in all patients.

(e) all participants will be given emergency phone numbers to contact should they have any significant symptoms out of working hours and can attend A&E if required.

2. Extra visits for blood tests additional to those of routine care will be undertaken with 10 visits over 7 months instead of the usual 2-3 visits in standard of care. Participants will have travel expenses reimbursed plus £200 in view of the inconvenience. In addition, telephone follow up will be held at weeks 6, 10, 14, 18 and 22 to identify any adverse events early.

3. There is some pain and discomfort associated with a blood test and patients will have multiple tests (10x) over 7 months. However, symptoms are likely to be minimal and the number of tests will be made clear to participants in the consent process.

4. Only those who are willing to use condoms or abstain during the trial will be eligible. This will ensure any detectable HBV or HIV during the withdrawal phase of the study, even though unlikely, will not be transmitted to sexual partners.

Where is the study run from?

King's College Hospital NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

May 2022 to October 2025

Who is funding the study?

British HIV Association (UK)

King's College Hospital Charity (UK)

Who is the main contact?

Dr Daniel Bradshaw, [daniel.bradshaw2@nhs.net](mailto:daniel.bradshaw2@nhs.net)

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Mariusz Racz

**Contact details**

KHPCTO

16th Floor Tower Wing, Guy's Hospital

Great Maze Pond

London

United Kingdom

SE1 9RT

+44 207 188 5732

mariusz.racz@kcl.ac.uk

**Type(s)**

Principal Investigator

**Contact name**

Dr Kosh Agarwal

**Contact details**

King's College Hospital

Denmark Hill

London

United Kingdom

SE5 9RS

+44 203 2997615

Kosh.agarwal@nhs.net

**Type(s)**

Scientific

**Contact name**

Dr Dan Bradshaw

**ORCID ID**

<http://orcid.org/0000-0001-7186-2482>

**Contact details**

Virus Reference Department

UK Health Security Agency

61 Colindale Avenue

London

United Kingdom

NW9 5EQ

+44 20 8327 6109

daniel.bradshaw2@nhs.net

# Additional identifiers

## EudraCT/CTIS number

2021-005910-32

## IRAS number

1004892

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

3633, IRAS 1004892

# Study information

## Scientific Title

REgimen optimisation: Feasibility of simplifying Nucleotide therapy in HIV/HBV coinfection (REFINE-B study)

## Acronym

REFINE-B

## Study objectives

Primary objectives:

1. What proportion of people with HIV and HBV infection, who may be eligible to take part in the study and are asked if they would participate, agree to be assessed for eligibility?
2. What proportion of those who are screened to see if they are eligible to take part in the study have undetectable levels of the blood marker HBV pgRNA?
3. What proportion of those who are screened to see if they are eligible to take part in the study have undetectable levels of the blood marker HBcrAg?
4. What proportion of people who meet eligibility criteria after screening proceed to consent to the study?
5. What proportion of people who attend for the first (baseline) study visit are still in the study at 24 weeks?
6. What proportion of people report new or worsening of existing medical problems during the study?

Secondary objectives:

1. What proportion of individuals have a liver enzyme ALT or AST increase  $> 3\times$  the level at the baseline visit, or  $>120\text{U/L}$ , at any point over 24 weeks?
2. What proportion of individuals have an HBV DNA level  $> 20\text{ IU/ml}$  at any point over 24 weeks?
3. What proportion of individuals have an HBV DNA level  $>200\text{ IU/ml}$  at any point over 24 weeks?
4. What proportion of individuals have an HIV-1 RNA level  $>50\text{ c/ml}$  at any point over 24 weeks?
5. What proportion of individuals have an HIV-1 RNA level  $>200\text{ c/ml}$  at any point over 24 weeks?
6. What proportion of individuals remain on simplified therapy at 24 weeks?
7. What is the change in HBsAg levels over 24 weeks?
8. What is the change in HBV pgRNA levels over 24 weeks?

9. What is the change in HBcrAg levels over 24 weeks?

10. What is the change in the quality of life assessed through questionnaires at baseline and 24 weeks?

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

Approved 07/07/2022, South Central - Berkshire B REC (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +442071048276; berkshireb.rec@hra.nhs.uk), ref: 22/SC/0184

### **Study design**

Interventional randomized controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

People with both Human immunodeficiency virus - the virus which causes HIV/AIDS - and Hepatitis B Virus infections

### **Interventions**

A single arm trial. All eligible participants will temporarily discontinue tenofovir or entecavir whilst continuing their other antiviral medicines. Individuals will be closely followed up for 6 months, with HBV, HIV and liver blood tests, before restarting tenofovir or entecavir.

### **Intervention Type**

Drug

### **Phase**

Phase IV

### **Drug/device/biological/vaccine name(s)**

Tenofovir disoproxil fumarate, entecavir monohydrate, tenofovir alafenamide

### **Primary outcome measure**

Feasibility of temporary simplification of antiviral therapy in HIV/HBV coinfection as determined at 24 weeks by:

1. % of those approached who agree to be assessed for eligibility
2. % of those screened with undetectable HBV pgRNA

3. % of those screened with undetectable HBcrAg
4. % of those eligible after screen who consent to the study
5. % of those participating at 24 weeks
6. % of those with Adverse Events by 24 weeks

### **Secondary outcome measures**

1. Proportion of individuals with a liver enzyme ALT or AST increase > 3x the level at the baseline visit, or >120 U/L, at baseline and weeks 2, 4, 8, 12, 16, 20, 24
2. Proportion of individuals with an HBV DNA level >20 IU/ml at baseline and weeks 2, 4, 8, 12, 16, 20, 24
3. Proportion of individuals with an HBV DNA level >200 IU/ml at baseline and weeks 2, 4, 8, 12, 16, 20, 24
4. Proportion of individuals with an HIV-1 RNA level >50 c/ml at weeks 4, 12 and 24
5. Proportion of individuals with an HIV-1 RNA level >200 c/ml at weeks 4, 12 and 24
6. Proportion of individuals remaining on simplified therapy at 24 weeks
7. HBsAg levels at baseline and weeks 12 and 24
8. HBV pgRNA levels at baseline and weeks 12 and 24
9. HBcrAg levels at baseline and weeks 12 and 24
10. Quality of life assessed through questionnaires at baseline and 24 weeks

### **Overall study start date**

20/05/2022

### **Completion date**

30/10/2025

## **Eligibility**

### **Key inclusion criteria**

1. HIV-1 antibody and HBsAg positive
2. Receiving
  - 2.1. Dolutegravir + tenofovir disoproxil fumarate/tenofovir alafenamide + lamivudine/emtricitabine, OR
  - 2.2. Darunavir with cobicistat/ritonavir + tenofovir disoproxil fumarate/tenofovir alafenamide + lamivudine/emtricitabine, OR
  - 2.3. Other antiretroviral combination including lamivudine/emtricitabine and tenofovir disoproxil fumarate/tenofovir alafenamide, where discontinuation of tenofovir would not be expected to lead to loss of HIV control\*, OR
  - 2.4. A tenofovir-free antiretroviral combination including lamivudine/emtricitabine, plus entecavir
3. Antiretroviral regimen stable for ≥6 months
4. HBV DNA <20 IU/ml and HIV-1 RNA <50 c/ml for at least 3 years. Note that blips are permitted.
5. HBV pgRNA <1.65 log<sub>10</sub> IU/ml at screen
6. HBcrAg < 3 log<sub>10</sub> IU/ml at screen
7. HBeAg negative and anti-HBe positive
8. HBsAg <10,000 IU/mL
9. CD4 >350 c/mm<sup>3</sup>
10. No significant hepatic fibrosis (Fibroscan ≤6kPa or liver biopsy <F2)
11. Provides written, informed consent
12. Age 18 years or older
13. Is willing to comply with protocol requirements

14. Is willing to use condoms or abstain during the trial  
\* This will be determined at the investigator's discretion

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

12

**Total final enrolment**

7

**Key exclusion criteria**

1. Other viral hepatitis coinfection including HDV antibody positive or HCV antigen or HCV RNA positive. Note HCV antibody positive with RNA or antigen negative is permitted.
2. History of known or suspected HBV resistance
3. History of HIV resistance to nucleos(t)ide reverse transcriptase inhibitors or integrase strand transfer inhibitors or protease inhibitors, where the resistance could be expected to compromise the efficacy of the tenofovir-free regimen
4. HIV-2
5. Non-viral hepatitis liver comorbidity including alcohol-associated, metabolic or autoimmune
6. Fibroscan >6kPa or liver biopsy ≥F2
7. ALT > 40 IU/L
8. Less than 18 years old
9. Pregnancy or breastfeeding
10. History of hepatocellular carcinoma
11. Any malignancy within previous 2 years, other than skin basocellular carcinoma
12. Non-HIV immunodeficiency including organ transplantation or medication-induced immunosuppression within previous 6 months
13. Any medical condition, including neurological or psychiatric conditions, which in the judgement of the investigator may impair a volunteer's ability to give informed consent or attend study visits

**Date of first enrolment**

21/08/2022

**Date of final enrolment**

01/03/2025

**Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

-

United Kingdom

-

## **Sponsor information**

**Organisation**

King's College Hospital NHS Foundation Trust

**Sponsor details**

UK Health Security Agency

61 Colindale Avenue

London

England

United Kingdom

NW9 5EQ

+44 747 3002700

daniel.bradshaw2@nhs.net

**Sponsor type**

Hospital/treatment centre

**Website**

<https://www.kch.nhs.uk/>

**ROR**

<https://ror.org/01n0k5m85>

## **Funder(s)**

**Funder type**

Research organisation

**Funder Name**

British HIV Association



**Alternative Name(s)**

BHIVA

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Associations and societies (private and public)

**Location**

United Kingdom

**Funder Name**

King's College Hospital Charity

## Results and Publications

**Publication and dissemination plan**

Peer reviewed scientific journals

Conference presentation

Other researchers will be able to request access to anonymised study data after the trial has finished, by a written request to the CI.

**Intention to publish date**

01/04/2026

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

daniel.bradshaw2@nhs.net

**IPD sharing plan summary**

Available on request

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No